Dynamics, Inc. (ASX: GID) announced today that clinical data about EndoBarrier®
Therapy, a breakthrough treatment for type 2 diabetes and/or
obesity, was presented at the 29th Annual Meeting of the American
Society for Metabolic & Bariatric Surgery (ASMBS) in San Diego.
ASMBS is the largest organization for bariatric surgeons in the world.
Interim data was previously presented at the 2012 Society of American
Gastrointestinal and Endoscopic Surgeons (SAGES) Postgraduate Course.
During a plenary session on "Emerging Technologies and Concepts,"
Ricardo V. Cohen, M.D., Center for the Surgical Treatment of Morbid
Obesity and Metabolic Disorders, Hospital Alemão Oswaldo Cruz, São
Paulo, Brazil, presented findings from his study, "Metabolic Improvement
in Type 2 Diabetes in Subjects without Severe Obesity with the
Endoscopic Duodenal-Jejunal Bypass Liner."
This non-randomized, single-arm, single-center study evaluated
EndoBarrier Therapy in 20 patients with uncontrolled type 2 diabetes and
a mean body mass index (BMI) of 30.0 kg/m2 (range: 23-36)
over a one-year period. Sixteen patients completed one year of
EndoBarrier Therapy with the following results: